ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Immunosuppressive tumour microenvironments are common in cancers such as metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC)Â (MASH-HCC)